Home › Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
 

Keywords :   


Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy

2015-12-02 02:15:49| drugdiscoveryonline Home Page

Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community

Tags: with daily activity trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »